An adenoviral vector-based mucosal vaccine is effective in protection against botulism

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 367-375

  Xu, Q ^a   Pichichero, M E ^a   Simpson, L L ^b   Elias, Md ^b   Smith, L A ^c   Zeng, M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EXOENZYME C3; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL IMMUNITY; BOTULISM; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; FEMALE; INOCULATION; LD 50; MOUSE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, SYNTHETIC;

ADENOVIRIDAE; ANIMALIA; MUS;

EID: 62549084249     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.181     Document Type: Article

References (54)

1. Villar RG, Elliott SP, Davenport KM. Botulism: The many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am 2006; 20: 313-327.
2. Atlas RM. Bioterriorism: From threat to reality. Annu Rev Microbiol 2002; 56: 167-185.
3. Montgomery VA, Makuch RS, Brown JE, Hack DC. The immunogenicity in humans of a botulinum type F vaccine. Vaccine 1999; 18: 728-735.
4. Takeda M, Kasai H, Torii Y, Mukamoto M, Kohda T, Tsukamoto K et al Protective effect of botulinum C/D mosaic toxoid against avian botulism. J Vet Med Sci 2006; 68: 325-330.
5. Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003; 21: 3110-3117.
6. Segelke B, Knapp M, Kadkhodayan S, Balhorn R, Rupp B. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc Natl Acad Sci USA 2004; 101: 6888-6893.
7. Woodward LA, Arimitsu H, Hirst R, Oguma K. Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 2003; 71: 2941-2944.
8. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000; 82: 955-966.
9. Oshima M, Hayakari M, Middlebrook JL, Atassi MZ. Immune recognition of botulinum neurotoxin type A: Regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol Immunol 1997; 34: 1031-1040.
10. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 2007; 25: 4273-4282.
11. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998; 66: 4817-4822.
12. Atassi MZ, Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 1999; 19 219-260.
13. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007; 75: 3043-3054.
14. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: Past, present, and future. Crit Rev Immunol 2007; 27: 303-318.
15. Baldwin MR, Tepp WH, Pier CL, Bradshaw M, Ho M, Wilson BA et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005; 73: 6998-7005.
16. Smith LA, Jensen MJ, Montgomery VA, Brown DR, Ahmed SA, Smith TJ. Roads from vaccines to therapies. Mov Disord 2004; 19: S48-S52.
17. Byrne MP, Titball RW, Holley J, Smith LA. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif 2000; 18: 327-337.
18. Boles J,West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P et al Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 2006; 47: 877-884.
19. Holley JL, Elmore M, Mauchline M, Minton N, Titball RW. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000; 19: 288-297.
20. Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001; 69: 5709-5715.
21. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006; 24: 849-862.
22. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-629.
23. Babiuk LA, Tikoo SK. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J Biotechnol 2000; 83: 105-113.
24. Xu Q, Arevalo MT, Pichichero ME, Zeng M. A new complementing cell line for replication-incompetent E1-deleted adenovirus propagation. Cytotechnology 2006; 51: 133-140.
25. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I et al Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367: 475-481.
26. Kobinger GP, Figueredo JM, Rowe T, Zhi Y, Gao G, Sanmiguel JC et al Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 2007; 25: 5220-5231.
27. Shu Y, Winfrey S, Yang ZY, Xu L, Rao SS, Srivastava I et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 2007; 25 1398-1408.
28. Hu RL, Liu Y, Zhang SF, Zhang F, Fooks AR. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 2007; 25: 5301-5307.
29. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006; 74: 4634-4643.
30. Zeng M, Xu Q, Hesek ED, Pichichero ME. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 2006; 24: 662-670.
31. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007; 25: 7540-7548.
32. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS et al. Botulinum toxin as a biological weapon. In: Henderson DA, Inglesby TV, O' Toole T (eds). Bioterrorism: Guidelines for Medical and Public Health Management. AMA Press: Chicago, IL, 2002, pp 141-165.
33. Caya JG, Agni R, Miller JE. Clostridium botulinum and the clinical laboratorian: A detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch Pathol Lab Med 2004; 128: 653-662.
34. Fujihashi K, Staats HF, Kozaki S, Pascual DW. Mucosal vaccine development for botulinum intoxication. Expert Rev Vaccines 2007; 6: 35-45.
35. Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW et al A novel neurotoxoid vaccine prevents mucosal botulism. J Immunol 2005; 174: 2190-2195.
36. Maddaloni M, Staats HF, Mierzejewska D, Hoyt T, Robinson A, Callis G et al. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 2006; 177: 5524-5532.
37. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, Chakrabarti BK et al Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003; 77: 10078-10087.
38. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME et al Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77: 6305-6313.
39. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
40. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 2003; 77: 8729-8735.
41. Papp Z, Babiuk LA, Baca-Estrada ME. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 1999; 17: 933-943.
42. Fischer L, Tronel JP, Pardo-David C, Tanner P, Colombet G, Minke J et al. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine 2002; 20: 3485-3497.
43. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
44. Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA et al. AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination. Biotechniques 2001; 31: 260-262.
45. Kimura K, Fujii N, Tsuzuki K, Murakami T, Indoh T, Yokosawa N et al The complete nucleotide sequence of the gene coding for botulinum type C1 toxin in the C-ST phage genome. Biochem Biophys Res Commun 1990; 171: 1304-1311.
46. Singh SR, Hulett K, Pillai SR, Dennis VA, Oh MK, Scissum-Gunn K. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 2006; 24: 1213-1224.
47. Russell MW, Wu HY. Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect Immun 1991; 59: 4061-4070.
48. Zeng M, Xu Q, Pichichero ME. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine 2007; 25: 3558-3594.
49. Watanabe I, Hagiwara Y, Kadowaki SE, Yoshikawa T, Komase K, Aizawa C et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 2002; 20: 3443-3455.
50. Arimitsu H, Lee JC, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M et al. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins. Clin Diagn Lab Immunol 2004; 11: 496-502.
51. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002; 99: 11346-11350.
52. Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 2001; 75: 11474-11482.
53. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73: 6729-6742.
54. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.